Yesterday Sarepta released its second quarter earnings report and included an update on their Duchenne muscular dystrophy program. We asked Sarepta to provide the community with a written update regarding their exon 51 confirmatory study, NDA submission, and plans for follow-on exons.

Read the update from Sarepta. To download the full recording, click here.


PPMD is grateful for the commitment by Sarepta to move as expeditiously as possible to get these trials up and running.

Views: 745

Comment

You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service